Market Overview

UPDATE: JMP Securities Reiterates On Esperion Therapeutics Inc Following Positive Trial Results


In a report published Thursday, JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating on Esperion Therapeutics Inc (NASDAQ: ESPR), and raised the price target from $34.00 to $53.00.

In the report, JMP Securities noted, “ETC-1002 demonstrates compelling efficacy and safety results with the Zetia combination showing potential for LDL-C reductions comparable to PCSK9 inhibitors; reiterate Market Outperform rating on Esperion Therapeutics and increase price target to $53 from $34. Esperion announced positive results from the Phase 2b trial comparing ETC-1002 to Zetia. The trial met its primary endpoint demonstrating significantly superior LDL-C lowering with ETC-1002 vs. Zetia, with reductions of 27-30% as a monotherapy. Moreover, the combination of ETC-1002 and Zetia resulted in LDL-C reductions of 43-48%, which we view as competitive vs. PCSK9 inhibitors with potential advantages of more convenient, once-a-day oral administration, and lower cost. As detailed below, we view the safety and tolerability profile as clean. We increase our risk-adjusted NPV-based price target to reflect increased probabilities of success in both the statin intolerant, and residual risk patient populations.”

Esperion Therapeutics Inc closed on Wednesday at $24.42.

Latest Ratings for ESPR

Mar 2019JP MorganUpgradesUnderweightNeutral
Dec 2018Goldman SachsInitiates Coverage OnSell
Oct 2018BTIG ResearchInitiates Coverage OnBuy

View More Analyst Ratings for ESPR
View the Latest Analyst Ratings

Posted-In: Jason N. Butler JMP SecuritiesAnalyst Color Price Target Analyst Ratings


Related Articles (ESPR)

View Comments and Join the Discussion!

Wi-LAN Inc Tumbles As Apple Inc. Wins In Court

UPDATE: Barrington Research Upgrades Gentherm Inc On Continued Solid Outlook